Sarepta Therapeutics Inc. (NASDAQ:SRPT) was upgraded by equities researchers at Royal Bank Of Canada from a “sector perform” rating to an “outperform” rating in a note issued to investors on Monday. The firm presently has a $83.00 target price on the stock. Royal Bank Of Canada’s price target would suggest a potential upside of 47.63% from the company’s previous close.

A number of other equities analysts also recently issued reports on SRPT. Oppenheimer Holdings Inc. reissued a “buy” rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research note on Sunday, July 17th. Piper Jaffray Cos. reissued a “sell” rating and set a $6.00 target price on shares of Sarepta Therapeutics in a research note on Saturday, June 4th. Robert W. Baird restated an “outperform” rating and issued a $23.00 price target on shares of Sarepta Therapeutics in a report on Thursday, May 26th. Vetr cut Sarepta Therapeutics from a “buy” rating to a “strong sell” rating and set a $17.28 price target on the stock. in a report on Wednesday, June 8th. Finally, Janney Montgomery Scott restated a “hold” rating on shares of Sarepta Therapeutics in a report on Thursday, May 26th. Two analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus target price of $51.01.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 56.22 on Monday. Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $58.87. The stock has a 50 day moving average price of $29.05 and a 200-day moving average price of $21.62. The firm’s market capitalization is $2.69 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/royal-bank-of-canada-upgrades-sarepta-therapeutics-inc-srpt-to-outperform.html

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period last year, the firm earned ($0.87) earnings per share. On average, analysts anticipate that Sarepta Therapeutics will post ($4.17) EPS for the current year.

In other Sarepta Therapeutics news, SVP David T. Howton sold 9,304 shares of the firm’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $465,200.00. Following the transaction, the senior vice president now directly owns 11,168 shares of the company’s stock, valued at $558,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares in the company, valued at $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SRPT. Teacher Retirement System of Texas raised its position in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. bought a new position in Sarepta Therapeutics during the second quarter valued at approximately $154,000. Quantitative Systematic Strategies LLC bought a new position in Sarepta Therapeutics during the second quarter valued at approximately $211,000. First Allied Advisory Services Inc. raised its position in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the period. Finally, National Planning Corp raised its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the period. 72.09% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.